Larimar Therapeutics Statistics
Share Statistics
Larimar Therapeutics has 64.03M
shares outstanding. The number of shares has increased by 0.35%
in one year.
| Shares Outstanding | 64.03M |
| Shares Change (YoY) | 0.35% |
| Shares Change (QoQ) | 0.35% |
| Owned by Institutions (%) | 99.41% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 1,147 |
| FTD / Avg. Volume | 0.11% |
Short Selling Information
The latest short interest is 5.97M, so 9.32% of the outstanding
shares have been sold short.
| Short Interest | 5.97M |
| Short % of Shares Out | 9.32% |
| Short % of Float | 16.87% |
| Short Ratio (days to cover) | 4.73 |
Valuation Ratios
The PE ratio is -2.94 and the forward
PE ratio is -0.92.
Larimar Therapeutics's PEG ratio is
-0.05.
| PE Ratio | -2.94 |
| Forward PE | -0.92 |
| PS Ratio | 0 |
| Forward PS | 0.3 |
| PB Ratio | 1.38 |
| P/FCF Ratio | -3.33 |
| PEG Ratio | -0.05 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Larimar Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.02,
with a Debt / Equity ratio of 0.03.
| Current Ratio | 8.02 |
| Quick Ratio | 8.02 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | -0.06 |
| Debt / FCF | -0.07 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-1,240,061.54 |
| Employee Count | 65 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -77.64% in the
last 52 weeks. The beta is 0.87, so Larimar Therapeutics's
price volatility has been higher than the market average.
| Beta | 0.87 |
| 52-Week Price Change | -77.64% |
| 50-Day Moving Average | 2.31 |
| 200-Day Moving Average | 5.09 |
| Relative Strength Index (RSI) | 37.72 |
| Average Volume (20 Days) | 1,035,108 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -90.89M |
| Net Income | -80.6M |
| EBITDA | -80.29M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -1.32 |
Full Income StatementBalance Sheet
The company has 33.22M in cash and 5.12M in
debt, giving a net cash position of 28.1M.
| Cash & Cash Equivalents | 33.22M |
| Total Debt | 5.12M |
| Net Cash | 28.1M |
| Retained Earnings | -269.16M |
| Total Assets | 170.18M |
| Working Capital | 143.35M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -70.76M
and capital expenditures -515K, giving a free cash flow of -71.28M.
| Operating Cash Flow | -70.76M |
| Capital Expenditures | -515K |
| Free Cash Flow | -71.28M |
| FCF Per Share | -1.16 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
